东诚药业(002675) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 686.93 million, representing a year-on-year increase of 6.13% compared to CNY 647.23 million in the same period last year[5]. - Net profit attributable to shareholders decreased by 61.55% to CNY 24.73 million from CNY 64.33 million year-on-year[5]. - Total operating revenue for the current period reached ¥686,928,164.92, an increase of 6.1% compared to ¥647,229,057.46 in the previous period[21]. - Net profit for the current period was ¥17,149,804.60, a decrease of 74.0% from ¥65,930,939.61 in the previous period[22]. - The profit attributable to the parent company's shareholders was ¥24,731,523.19, down from ¥64,327,510.75, representing a decline of 61.6%[22]. - Total comprehensive income for the period was CNY 14,432,666.35, a decrease from CNY 64,043,153.93 in the previous period[23]. - Basic and diluted earnings per share were both CNY 0.0300, down from CNY 0.0780 in the previous period[23]. Cash Flow and Financial Position - The net cash flow from operating activities increased significantly by 168.98%, reaching CNY 114.04 million, compared to a negative cash flow of CNY 165.32 million in the previous year[5]. - Net cash flow from operating activities was CNY 114,036,490.30, a significant improvement from a negative CNY 165,318,835.72 in the previous period[25]. - Cash inflow from investment activities totaled CNY 244,977,797.84, compared to CNY 55,664,969.52 in the previous period[25]. - Net cash flow from financing activities was negative CNY 105,346,407.51, a decline from a positive CNY 577,121,865.51 in the previous period[25]. - The ending balance of cash and cash equivalents was CNY 670,718,795.06, slightly up from CNY 668,932,589.63 in the previous period[25]. - The company’s cash and cash equivalents decreased from 755,972,381.28 CNY to 697,376,537.69 CNY, reflecting a decline of approximately 7.5%[17]. - The company reported a total cash outflow from operating activities of CNY 591,630,360.78, down from CNY 824,778,062.09 in the previous period[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 8.69 billion, a 0.61% increase from CNY 8.63 billion at the end of the previous year[5]. - Total assets increased to ¥8,686,979,590.40 from ¥8,634,677,996.44, showing a growth of 0.6%[19]. - Total liabilities rose to ¥3,287,098,674.03, slightly up from ¥3,263,210,041.55, indicating an increase of 0.7%[19]. - Current liabilities decreased to ¥1,542,348,228.08 from ¥1,753,956,120.72, a reduction of 12.0%[19]. - Non-current liabilities increased to ¥1,744,750,445.95 from ¥1,509,253,920.83, reflecting a rise of 15.6%[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,576, with no preferred shareholders[12]. - The company reported a total of 27,654,757 shares held by PACIFIC RAINBOW INTERNATIONAL, accounting for 3.35% of total shares[14]. - The top ten unrestricted shareholders collectively hold 124,888,049 shares, with Yantai Dongyi Biological Engineering Co., Ltd. being the largest shareholder[14]. Operational Segments - The sales revenue from the raw material drug segment was CNY 321.50 million, up 11.10% year-on-year, primarily due to increased sales of heparin products[9]. - The sales revenue from the formulation segment decreased by 6.78% to CNY 86.63 million, while the nuclear medicine segment saw a slight decline of 0.63% to CNY 231.20 million[13]. Expenses and Financial Management - The company reported a significant increase in financial expenses by 536.48%, attributed to increased interest expenses from equity financing repurchase and reduced exchange gains[13]. - Research and development expenses were ¥44,008,471.83, slightly down from ¥45,209,265.30, a decrease of 2.7%[22]. - The company paid CNY 168,579,902.52 to employees, an increase from CNY 152,583,106.37 in the previous period[25]. - The company experienced a 271.36% increase in credit impairment losses, primarily due to provisions for bad debts on receivables[13]. Future Outlook - The company is currently exploring market expansion opportunities and new product development strategies[15].